Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG0370

Prrc2c Knockout Hepa 1-6 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Liver

  • Disease:

    Hepatocellular carcinoma

  • Gene Species:

    Mus musculus (Mouse)

The Prrc2c Knockout Hepa 1-6 Cell Line is a CRISPR/Cas9-edited knockout cell line targeting Prrc2c in the Hepa 1-6 mouse hepatocellular carcinoma model. PRRC2C is a component of the mRNA cap-binding complex that interacts with eIF4G and operates downstream of mTORC1, regulating translation of mRNAs involved in cell proliferation and survival. This knockout model enables investigation of Prrc2c function in translation regulation, hepatocellular carcinoma progression, and oncogenic signaling. It is suitable for applications such as western blotting, RNA-seq, polysome profiling, and cell proliferation assays, providing a relevant hepatic context for cancer research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Hepa 1-6

    Morphology

    Epithelial-like

    Gene Name

    Prrc2c

    Gene Species

    Mus musculus (Mouse)

    Gene Identifier

    NCBI Gene ID 226562

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The Prrc2c Knockout Hepa 1-6 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the Hepa 1-6 mouse hepatocellular carcinoma cell line, featuring targeted disruption of the Prrc2c gene. This loss-of-function model enables the investigation of Prrc2c-dependent mechanisms in a hepatic cancer context, providing a powerful tool for dissecting its role in mRNA processing and translation regulation. The edited cell line retains the core characteristics of the parental Hepa 1-6 line while lacking functional Prrc2c expression, facilitating comparative studies between wild-type and knockout states.

Hepa 1-6 is a well-established hepatocellular carcinoma cell line originating from a C57L mouse tumor. It serves as a relevant in vitro system for studies of liver metabolism, detoxification, and protein synthesis, closely mimicking the hepatic environment. The cell line??s tumorigenic properties and epithelial morphology make it particularly suitable for examining oncogenic processes and hepatocellular carcinoma progression in a genetically defined background.

PRRC2C functions as a component of the mRNA cap-binding complex, where it interacts with eIF4G and other eukaryotic translation initiation factors to modulate cap-dependent translation. It operates downstream of mTORC1 signaling, which is known to phosphorylate and regulate translation initiation components, and may also be transcriptionally activated by MYC. Through these interactions, PRRC2C influences the translation of select mRNAs encoding cell cycle regulators and translation initiation factors, thereby contributing to translational control of proliferation and survival pathways. The knockout thus disrupts a node linking growth signals to the protein synthesis machinery.

In the Hepa 1-6 background, Prrc2c disruption provides a physiologically relevant model to study how translation regulation impacts hepatocellular carcinoma cell behavior. Since liver cells rely heavily on protein synthesis for metabolic and proliferative functions, loss of PRRC2C likely alters the translation landscape of mRNAs critical for cell growth and stress responses. This model enables dissection of Prrc2c-mediated contributions to hepatocarcinogenesis and may reveal vulnerabilities associated with dysregulated translation in liver cancer.

The Prrc2c Knockout Hepa 1-6 Cell Line is suited for a broad range of research applications, including studies of translation initiation, mRNA processing, and oncogenic signaling. Typical assays include western blotting and RT-qPCR for expression analysis, RNA-seq for transcriptome profiling, polysome profiling to assess translational efficiency, and functional assays such as cell proliferation, migration, and flow cytometry-based analyses. Researchers can employ this model to explore the interplay between mTORC1/MYC signaling and translational control in hepatocellular carcinoma. For further information or custom inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)